Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 6, 2008, Pages 394-396

  Keynan, Yoav ^a   Larios, Oscar E ^a   Wiseman, Marni C ^a   Plourde, Marie ^b   Ouellette, Marc ^b   Rubinstein, Ethan ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Cutaneous leishmaniasis; Leishmaniasis; Phlebotomus

Indexed keywords

ANTIBIOTIC AGENT; ATOVAQUONE PLUS PROGUANIL; FLUCONAZOLE; MILTEFOSINE; ORAL CONTRACEPTIVE AGENT; STEROID; STIBOGLUCONATE SODIUM;

ABDOMINAL PAIN; ADULT; AFGHANISTAN; ARTICLE; CANADA; CASE REPORT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LOOSE FECES; MALARIA; MALARIA CONTROL; MALE; POLYMERASE CHAIN REACTION; PYODERMA GANGRENOSUM; SKIN BIOPSY; SKIN LEISHMANIASIS; SKIN ULCER; SOLDIER; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 58149236692     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/802710     Document Type: Article

References (18)

1. World Health Organization. The world health report: Changing history. Geneva: World Health Organization, 2004:1-96. 〈http://www.who.int/whr/2004/ en/report04_en.pdf〉 (Version current at July 30, 2007).
2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561-77.
3. Center for Disease Control and Prevention (CDC). Update: Cutaneous leishmaniasis in U.S. military personnel - Southwest/ Central Asia, 2002-2004. MMWR Morb Mortal Wkly Rep 2004;53:264-5.
4. Aronson NE, Sanders JW, Moran KA. In harm's way: Infections in deployed American military forces. Clin Infect Dis 2006;43:1045-51.
5. Reithinger R, Coleman PG. Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: Cost-effectiveness of an operational program in a complex emergency setting. BMC Infect Dis 2007;7:3.
6. Magill AJ, Grogl M, Gasser RA, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993;328:1383-7.
7. Shani-Adir A, Kamil S, Rozenman D, et al. Leishmania tropica in northern Israel: A clinical overview of an emerging focus. J Am Acad Dermatol 2005;53:810-5.
8. Faulde MK, Heyl G, Amirih ML. Zoonotic cutaneous leishmaniasis, Afghanistan. Emerg Infect Dis 2006;12:1623-4.
9. Herwaldt BL. Leishmanisis. Lancet 1999;354:1191-9.
10. Ozgoztasi O, Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 1997;36:61-3.
11. Alkhawajah AM, Larbi E, al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: Intra-muscular versus intralesional administration. Ann Trop Med Parasitol 1997;91:899-905.
12. Reithinger R, Mohsen M, Wahid M, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: A randomized, controlled trial. Clin Infect Dis 2005;40:1148-55.
13. Bhattacharya SK, Jha TK, Sundar S, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004;38:217-21.
14. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian leishmaniasis. N Engl J Med 2002;347:1739-46.
15. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72.
16. Hadighi R, Boucher P, Khamesipour A, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 2007;101:1319-22.
17. Reithinger R, Leslie T, Mohsen M, et al. A randomized controlled trial to test the efficacy of miltefosine against Leishmania tropica in Kabul, Afghanistan. Third World Congress on Leishmaniasis, 2005.
18. Soto J, Soto P. Oral miltefosine to treat leishmaniasis. Biomedica 2006;26(Suppl 1):207-17.